NCT00003816 arm group 505d07bbc5b4b2efd120c5b762c2cb36 [clinicaltrials_resource:NCT00003816/arm-group/505d07bbc5b4b2efd120c5b762c2cb36]
arm group [clinicaltrials_vocabulary:arm-group]
NCT00003816 arm group 505d07bbc5b4b2efd120c5b762c2cb36 [clinicaltrials_resource:NCT00003816/arm-group/505d07bbc5b4b2efd120c5b762c2cb36]
Bio2RDF identifier
NCT00003816/arm-group/505d07bbc5b4b2efd120c5b762c2cb36
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltri ...... 5d07bbc5b4b2efd120c5b762c2cb36
description [clinicaltrials_vocabulary:description]
Patients receive fludarabine I ...... over 1 hour on days -3 and -2.
identifier
clinicaltrials_resource:NCT00003816/arm-group/505d07bbc5b4b2efd120c5b762c2cb36
title
NCT00003816 arm group 505d07bbc5b4b2efd120c5b762c2cb36
@en
type
label
NCT00003816 arm group 505d07bb ...... d07bbc5b4b2efd120c5b762c2cb36]
@en